• Download mobile app
15 Jul 2024, Edition - 3289, Monday

Trending Now

  • My aim is to make India the third most economically powerful country. I’ve vowed to work three times more in my third term: PM Modi to the Indians in Russia
  • Rahul Gandhi who goes to Hatras does not bother about the deaths in Kallakuruchi: Union Minister L Murugan.
  • All those who killed Armstrong will be arrested and brought to justice: MK Stalin promises Armstrong ‘s parents and his wife
  • Law and Order will not get any better by changing the police officers. Law and Order has totally collapsed in DMK’s regime.: EPS

Businesswire

Aragen Bioscience, Inc. and University of Technology, Sydney Enter Into MoU to Support and Accelerate Biologics R&D in Australia

by businesswireindia.com

Share
Business Wire India
Aragen Bioscience, Inc, a fully owned subsidiary of GVK BIO and a leading large molecule CRO, and University of Technology Sydney (UTS), the top-ranked young university in Australia, are pleased to announce a collaboration to accelerate biologics R&D in Australia.

This partnership between UTS and Aragen unites the capabilities, experience, and expertise of two leading organizations to assist the Australian biopharma and biotech industries advance their ideas into medicines.

“Under this collaboration, customers can leverage Aragen’s proprietary, cutting edge, royalty-free CHO DG-44 expression system for therapeutic antibody production. Downstream clinical development and manufacturing requirements can be met through UTS’s Biologics Innovation Facility (BIF), providing the Australian Biopharmaceutical Industry with a seamless solution from Concept through Clinic,” said Dr. Axel Schleyer, CEO, Aragen Bioscience.

“We are delighted to partner with one of the top Australian institutions – UTS which has the infrastructure and knowhow to support large molecule clinical development,” said Manni Kantipudi, Chairman, Aragen, & Chief Executive Officer, GVK BIO. “The Aragen team is recognized globally for its antibody research, having discovered three Novel Biological Entities (NBE’s) that are now commercial. Through this collaboration with UTS, we expect to support the local industry by bringing together knowhow, experience, and world class infrastructure that marries speed, innovation, and costs.”

UTS Faculty of Science Business Development Manager, Dr Andrew Groth, said: “UTS welcomes the strategic partnership with Aragen to provide comprehensive but affordable cell line and expression technology solutions to Australian research communities and start-ups, to tackle the critical bottleneck during pre- and early-clinical stages of biologics development.”
Source: Businesswire
COIMBATORE WEATHER